Recent changes in trends of opioid overdose deaths in North America.
Analgesics, opioid
British Columbia
Canada
Death
Drug overdose
Ontario
Prescription drug
United States
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
31 08 2020
31 08 2020
Historique:
received:
11
04
2020
accepted:
19
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
2
9
2021
Statut:
epublish
Résumé
As several regulatory and environmental changes have occurred in North America, trends in overdose deaths were examined in the United States (US), Ontario and British Columbia (BC), including changes in consumption levels of prescription opioids (PO) and overdose deaths, changes in correlations between consumption levels of PO and overdose deaths and modeled differences between observed and predicted overdose deaths if no changes had occurred. Consumption levels of PO included defined daily doses for statistical purposes per million inhabitants per day for the US and Canada (2001-2015). Overdose deaths included opioid overdose deaths for the US (2001-2017) and Ontario (2003-2017) and illicit drug overdose deaths for BC (2001-2017). The analytic techniques included structural break point analyses, Pearson product-moment correlations and multivariate Gaussian state space modeling. Consumption levels of PO changed in the US in 2010 and in Canada in 2012. Overdose deaths changed in the US in 2014 and in Ontario and BC in 2015. Prior to the observed changes in consumption levels of PO, there were positive correlations between consumption levels of PO and overdose deaths in the US (r = 0.99, p < 0.001) and Ontario (r = 0.92, p = 0.003). After the observed changes in consumption levels of PO, there was a negative correlation between consumption levels of PO and overdose deaths in the US (r = - 0.99, p = 0.002). Observed overdose deaths exceeded predicted overdose deaths by 5.7 (95% Confidence Interval [CI]: 4.8-6.6), 3.5 (95% CI: 3.2-3.8) and 21.8 (95% CI: 18.6-24.9) deaths per 100,000 people in the US, Ontario and BC, respectively in 2017. These excess deaths corresponded to 37.7% (95% CI: 31.9-43.6), 39.2% (95% CI: 36.3-42.1) and 72.2% (95% CI: 61.8-82.6) of observed overdose deaths in the US, Ontario and BC, respectively in 2017. The opioid crisis has evolved in North America, as a sizeable proportion of overdose deaths are now attributable to the several regulatory and environmental changes. These findings necessitate substance use policies to be conceptualized more broadly as well as the continued expansion of harm reduction services and types of pharmacotherapy interventions.
Sections du résumé
BACKGROUND
As several regulatory and environmental changes have occurred in North America, trends in overdose deaths were examined in the United States (US), Ontario and British Columbia (BC), including changes in consumption levels of prescription opioids (PO) and overdose deaths, changes in correlations between consumption levels of PO and overdose deaths and modeled differences between observed and predicted overdose deaths if no changes had occurred.
METHODS
Consumption levels of PO included defined daily doses for statistical purposes per million inhabitants per day for the US and Canada (2001-2015). Overdose deaths included opioid overdose deaths for the US (2001-2017) and Ontario (2003-2017) and illicit drug overdose deaths for BC (2001-2017). The analytic techniques included structural break point analyses, Pearson product-moment correlations and multivariate Gaussian state space modeling.
RESULTS
Consumption levels of PO changed in the US in 2010 and in Canada in 2012. Overdose deaths changed in the US in 2014 and in Ontario and BC in 2015. Prior to the observed changes in consumption levels of PO, there were positive correlations between consumption levels of PO and overdose deaths in the US (r = 0.99, p < 0.001) and Ontario (r = 0.92, p = 0.003). After the observed changes in consumption levels of PO, there was a negative correlation between consumption levels of PO and overdose deaths in the US (r = - 0.99, p = 0.002). Observed overdose deaths exceeded predicted overdose deaths by 5.7 (95% Confidence Interval [CI]: 4.8-6.6), 3.5 (95% CI: 3.2-3.8) and 21.8 (95% CI: 18.6-24.9) deaths per 100,000 people in the US, Ontario and BC, respectively in 2017. These excess deaths corresponded to 37.7% (95% CI: 31.9-43.6), 39.2% (95% CI: 36.3-42.1) and 72.2% (95% CI: 61.8-82.6) of observed overdose deaths in the US, Ontario and BC, respectively in 2017.
CONCLUSIONS
The opioid crisis has evolved in North America, as a sizeable proportion of overdose deaths are now attributable to the several regulatory and environmental changes. These findings necessitate substance use policies to be conceptualized more broadly as well as the continued expansion of harm reduction services and types of pharmacotherapy interventions.
Identifiants
pubmed: 32867799
doi: 10.1186/s13011-020-00308-z
pii: 10.1186/s13011-020-00308-z
pmc: PMC7457770
doi:
Substances chimiques
Analgesics, Opioid
0
Illicit Drugs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Subventions
Organisme : CIHR
Pays : Canada
Références
JAMA. 2012 Nov 14;308(18):1863-4
pubmed: 23150005
Brookings Pap Econ Act. 2017 Spring;2017:397-476
pubmed: 29033460
Drug Alcohol Rev. 2014 Jan;33(1):19-26
pubmed: 24261474
J Pain Palliat Care Pharmacother. 2015 Jun;29(2):102-14
pubmed: 26095479
Addiction. 2019 Sep;114(9):1602-1613
pubmed: 31166621
Inj Prev. 2016 Aug;22(4):288-90
pubmed: 26195562
Prev Med. 2018 Feb;107:109-113
pubmed: 29126920
Lancet Public Health. 2019 Feb;4(2):e81-e82
pubmed: 30579840
Drug Alcohol Depend. 2012 Sep 1;125(1-2):8-18
pubmed: 22857878
N Engl J Med. 2017 Feb 16;376(7):605-607
pubmed: 28199808
Inj Prev. 2013 Oct;19(5):326-30
pubmed: 23322257
Eur Addict Res. 2018;24(2):53-59
pubmed: 29627831
Drug Alcohol Depend. 2013 Sep 1;132(1-2):81-6
pubmed: 23399467
JAMA Intern Med. 2015 Oct;175(10):1642-9
pubmed: 26280092
Pain Med. 2012 Mar;13(3):434-42
pubmed: 22299725
N Engl J Med. 2015 Apr 16;372(16):1573-4
pubmed: 25875268
Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15078-83
pubmed: 26575631
J Safety Res. 2012 Sep;43(4):283-9
pubmed: 23127678
MMWR Morb Mortal Wkly Rep. 2014 Oct 10;63(40):881-5
pubmed: 25299603
Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):248-251
pubmed: 29911821
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Pharmacoepidemiol Drug Saf. 2017 May;26(5):587-591
pubmed: 28101968
Am J Prev Med. 2006 Dec;31(6):506-11
pubmed: 17169712
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
Res Social Adm Pharm. 2015 Nov-Dec;11(6):901-8
pubmed: 25769501
Int J Drug Policy. 2019 Dec;74:174-180
pubmed: 31627159
CMAJ. 2016 Jun 14;188(9):673
pubmed: 27091798
JAMA. 2018 Dec 18;320(23):2448-2460
pubmed: 30561481
BMC Med. 2016 Mar 10;14:42
pubmed: 27001105
CMAJ. 2018 Jan 15;190(2):E35-E36
pubmed: 29335260
N Engl J Med. 2016 Jul 7;375(1):44-53
pubmed: 27332619
Drug Alcohol Depend. 2013 Sep 1;132(1-2):95-100
pubmed: 23410617
MMWR Morb Mortal Wkly Rep. 2017 Jul 07;66(26):697-704
pubmed: 28683056
JAMA Psychiatry. 2014 Jul 1;71(7):821-6
pubmed: 24871348
CMAJ Open. 2014 Oct 01;2(4):E256-61
pubmed: 25485251
N Engl J Med. 2017 Apr 20;376(16):1502-1504
pubmed: 28423291
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
Subst Abuse Treat Prev Policy. 2014 Oct 27;9:43
pubmed: 25352167
JAMA. 2011 Apr 6;305(13):1315-21
pubmed: 21467284
Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):438-42
pubmed: 23319301
CMAJ. 2016 Dec 6;188(17-18):1240-1244
pubmed: 27821465
Natl Vital Stat Rep. 2016 Dec;65(10):1-15
pubmed: 27996932
BMJ. 2018 Aug 29;362:k3207
pubmed: 30158106